Why the FDA should not approve an ineffective multicancer screening test

An FDA advisory committee recommends approving Grail’s multi-cancer screening test. A cancer screening researcher disagrees.

Grail的多癌种血液筛查试验未能在替代终点上显示获益，FDA顾问委员会却建议批准，作者认为缺乏降低癌症死亡率的证据。文章还指出，新法案将使联邦医保快速覆盖该检测，可能带来每年数百亿美元的支出。